The Vestibular Catastrophe, Part 2: Ozempic, Mounjaro, and the Three Pathways of Organ Destruction (Updated: 12/14/2025)

Photo by Serg Balak on Unsplash

The sheer volume of questions I receive indicates that a critical awareness shift is underway in the vestibular community. Clinicians, physicians, and patients are now seeing the massive statistical risk posed by GLP-1 receptor agonists—Ozempic (Semaglutide), Mounjaro (Tirzepatide), and Wegovy—firsthand. (Toraih et al., 2025) Yet one question remains unanswered:

How does this drug actually cause damage?

The literature proves the statistical hazard, but the precise mechanism—the scientific blueprint for the destruction of the vestibular system—is where the confusion lies. (Toraih et al., 2025)

This article is your Part 2: a definitive deep dive that unpacks the three specific, destructive pathways by which these medications attack the labyrinth and the brain, transforming a metabolic solution into a neurological and microvascular catastrophe.

Methodology Context: Understanding the Data’s Authority and Limitations

We base this analysis on the immense authority of the Toraih et al. (2025) study, which utilized 496,756 patient records. (Toraih et al., 2025) However, we must view the data through a scientifically critical lens:

The Authority (Pros)

The study employed Propensity Score Matching among nearly half a million patients, which successfully isolated the risk and confirmed that the association is independent of underlying comorbidities (diabetes and obesity). (Toraih et al., 2025) This methodological rigor gives the high Hazard Ratios (HRs)—approaching 5.0—unprecedented weight. (Toraih et al., 2025)

The Caveats (Cons)

As a retrospective study, the findings establish an association, not absolute causation. (D’Amico et al., 2025) Relying solely on ICD-10 codes likely underreports mild symptoms. (Leventhal & Rajiv, 2020) It lacks objective functional testing (e.g., VNG, vHIT, Rotatory Chair, CDP, or VEMPs) to characterize the type and severity of vestibular loss precisely. Therefore, we must treat the findings with clinical precision, always seeking objective confirmation in our own practice.

1. Peripheral Damage: Global Labyrinthine Destruction and Neuritis

The pathology is a systemic assault on all components of the peripheral vestibular apparatus, including the Semicircular Canals (SCCs), the otolith organs, and the Vestibulocochlear Nerve (CN VIII).

• Microvascular Compromise and EP Crisis: Drug-induced nitric oxide (NO)- mediated vasodilation destabilizes the Stria Vascularis, compromising its energy supply. This compromises the Endolymphatic Potential (EP). The EP is the inner ear’s massive electrical battery—a sustained positive charge of +80 mV actively generated by the Stria Vascularis. (Salt et al., 1987) Disrupting this essential charge leads directly to fluid and electrical stress (hydrops), which causes both dizziness and hearing loss. (Toraih et al., 2025)

• Effect on SCCs: This electrical and fluid collapse immediately compromises the function of the SCCs’ ampullary receptors (crista ampullaris), leading to transient canal paresis or functional hypofunction.

• Vestibular Nerve Ischemia: The systemic microvascular instability introduces a high risk of transient ischemia (lack of blood flow) to the Vestibular Nerve (CN VIII) via the internal auditory artery. (Toraih et al., 2025) This direct vascular insult causes the neuronal damage that underpins the development of Vestibular Neuronitis. (GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Type 2 Diabetes, 2025)

• Otolithic Destruction: Sustained electrical and vascular stress accelerates oxidative stress and mitochondrial failure in the utricular macula’s supporting cells. This drives Utricular Macular Degeneration, causing the detachment of otoconia and subsequent BPPV. (Whitman et al., 2016)

2. Central Damage: VNC Corruption and Total Adaptive Failure

The drug actively hijacks the brain’s highest control centers, destroying the fundamental mechanisms of balance adaptation.

• BBB Penetration and Central Targets: The drug’s molecular structure allows it to cross the Blood-Brain Barrier (BBB)—a highly selective membrane that protects the central nervous system. (West et al., 2025)

• VNC Corruption and VOR Failure: Once centralized, the drug binds intensely to receptors within the Vestibular Nuclei Complex (VNC), the Area Postrema, and the Nucleus Tractus Solitarius (NTS). (Dissociable hindbrain GLP1R circuits for satiety and aversion, 2024) This chemical binding alters neuronal excitability, disrupting the brain’s capacity to calibrate Vestibulo-Ocular Reflex (VOR) gain. (Toraih et al., 2025)

• Autonomic Dysregulation (NTS): NTS binding modulates baroreflex sensitivity. This profoundly impairs the body’s ability to initiate compensatory hemodynamic responses to postural changes, thereby directly causing the orthostatic dizziness often reported.

• Destruction of Neuroplasticity: The sustained chemical pressure exerted by the drug drives the VNC into a state of chemical chaos, preventing neuroplastic change. (Toraih et al., 2025)

3. Systemic Threat: The Microvascular Extravaganza

The pathological process attacks all metabolically demanding microcirculations, confirming this is a systemic vascular disease. (Toraih et al., 2025)

• Vestibular Nerve Vulnerability: Vascular compromise directly impairs the afferent sensory neurons of the vestibular nerve (CN VIII). Unlike many other peripheral nerves, the vestibular nerve lacks robust protective mechanisms, rendering it exquisitely sensitive to ischemic stress induced by GLP-1RA-mediated vascular dysregulation. (Toraih et al., 2025)

• Cochlear and Endolymphatic Effects: The vascular collapse of the Stria Vascularis affects the shared fluid system, causing compromise of the ‘Organ of Corti’, resulting in hearing loss and tinnitus. (Toraih et al., 2025)

• Retinal Risk: Clinical reports of visual darkness suggest a real threat of ‘retinal vascular insufficiency’ in the highly metabolically active macula of the eye. (Malerbi et al., 2025)

Conclusion: The high Hazard Ratios are justified by this multi-system attack. GLP-1RAs induce Pharmacological Vestibulotoxicity, causing irreversible peripheral damage (Macular Degeneration, Neuritis, Canal Paresis) and relentless central corruption (VNC Modulation). (GLP-1 Receptor Agonists and Vision Risk, 2025) This pathology inevitably leads to maladaptive sensory strategies and chronic disequilibrium that manifest as severe dizziness and balance disorders. We must treat the patient experiencing dizziness while taking these medications with the urgency reserved for systemic organ failure.

Brian Werner, PT, MPT, is a physical therapist who has been specializing in vestibular and balance disorders for over a quarter of a century. He is the founder of the FYZICAL Balance Paradigm and one of the co-founders of FYZICAL, LLC, Balance Center Division with Dr. Daniel Deems, MD, PhD, where he serves as the National Director of Vestibular Education & Training.

References

Toraih, E. A., Alenezy, A., Hussein, M. H., Hashmat, S., Mummadi, S., Alrawili, N. F., Abdelmaksoud, A., & Fawzy, M. S. (2025). The Risk of Vestibular Disorders with Semaglutide and Tirzepatide: Findings from a Large Real-World Cohort. Biomedicines, 13(5), 1049.

Leventhal & Rajiv. (2020). Research: ICD-10 Codes Perform Poorly in Capturing COVID-19-Related Symptoms. https://www.hcinnovationgroup.com/finance-revenue-cycle/icd-10/news/21150761/research-icd-10-codes-perform-poorly-in-capturing-covid-19-related-symptoms

Malerbi, F.K., Bertoluci & M.C. (2025). Semaglutide, type 2 diabetes, and the risk of nonarteritic anterior ischemic optic neuropathy. International Journal of Retina and Vitreous 11. https://journalretinavitreous.biomedcentral.com/articles/10.1186/s40942-024-00622-9

Salt, N., A., Melichar, Ivo, Thalmann & Ruediger. (1987). Mechanisms of endocochlear potential generation by stria vascularis. Laryngoscope 97. https://pubmed.ncbi.nlm.nih.gov/3613802/

(2025). GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Type 2 Diabetes. JAMA Network Open 8. https://doi.org/10.1001/jamanetworkopen.2025.26321

Whitman, T., G., Baloh & W., R. (2016). Seasonality of Benign Paroxysmal Positional Vertigo. JAMA Otolaryngology–Head & Neck Surgery 142. https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/1936464

West, J., Li, M., Wong, S. & al., e. (2025). Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review. Neurology and Therapy 14. https://link.springer.com/article/10.1007/s40120-025-00724-y

(2024). Dissociable hindbrain GLP1R circuits for satiety and aversion. Nature 632. https://www.nature.com/articles/s41586-024-07685-6

(2025). GLP-1 Receptor Agonists and Vision Risk. American Optometric Association. https://www.aoa.org/news/clinical-eye-care/public-health/glp-1-receptor-agonists-and-vision-risk